---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000142"
form_type: "8-K/A"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:13:22.326256+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone

## Summary
- Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
- Issued 2,397,023 contingent shares at $5.2148/share, representing $12.5M value.
- Shares issued to Rallybio as seller under July 2025 ENPP1 JV acquisition.
- Prospectus supplement filed August 29, 2025 to register shares for resale.
- Filing amends prior 8-K from July 8, 2025 regarding the original acquisition.

## SEC filing metadata
- accession: 0001601830-25-000142
- form_type: 8-K/A
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/0001601830-25-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000142/rxrx-20250708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000142
- JSON: https://secwatch.observer/filing/0001601830-25-000142.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.